Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	calcium ion binding	GPD2 DCHS2 FAT4 PAMR1 MATN2 DAG1 ITIH1 RYR2 FAT1 HMCN1 MEGF8 VCAN LTBP4 UNC13A	4.19e-05	749	106	14	GO:0005509
GeneOntologyMolecularFunction	extracellular matrix structural constituent	FRAS1 RELN MATN2 HMCN1 VCAN LTBP4 MUC5AC	6.52e-05	188	106	7	GO:0005201
GeneOntologyMolecularFunction	serine-type peptidase activity	TPSAB1 RELN PAMR1 CTRC TYSND1 ADAM17 TPSB2	1.19e-04	207	106	7	GO:0008236
GeneOntologyMolecularFunction	serine hydrolase activity	TPSAB1 RELN PAMR1 CTRC TYSND1 ADAM17 TPSB2	1.38e-04	212	106	7	GO:0017171
GeneOntologyMolecularFunction	protein kinase A regulatory subunit binding	ARFGEF2 RYR2 PRRC1	3.07e-04	25	106	3	GO:0034237
GeneOntologyMolecularFunction	integrin binding	ADAM18 APP ITGA9 ITGAL ADAM17 LTBP4	3.44e-04	175	106	6	GO:0005178
GeneOntologyMolecularFunction	serine-type endopeptidase activity	TPSAB1 PAMR1 CTRC TYSND1 ADAM17 TPSB2	5.32e-04	190	106	6	GO:0004252
GeneOntologyMolecularFunction	tumor necrosis factor binding	A2M ADAM17	5.76e-04	7	106	2	GO:0043120
GeneOntologyMolecularFunction	peptidase activity	TPSAB1 RELN PAMR1 ADAM18 NPEPPS CTRC TYSND1 UCHL3 PAN2 ADAM17 TPSB2	7.10e-04	654	106	11	GO:0008233
GeneOntologyMolecularFunction	dolichyl-phosphate-mannose-protein mannosyltransferase activity	TMTC1 TMTC3	7.66e-04	8	106	2	GO:0004169
GeneOntologyMolecularFunction	cell adhesion molecule binding	FLNA FLNB ADAM18 APP ITGA9 ITGAL ADAM17 PLEC LTBP4 HDLBP	1.32e-03	599	106	10	GO:0050839
GeneOntologyMolecularFunction	guanylate kinase activity	MAGI3 CARD11	1.49e-03	11	106	2	GO:0004385
GeneOntologyCellularComponent	extracellular matrix	A2M TPSAB1 FRAS1 RELN MATN2 DAG1 MUC5B ADAMTSL3 ITIH1 HMCN1 VCAN CSPG4 LTBP4 MUC5AC PLXNA2 TPSB2	2.57e-07	656	108	16	GO:0031012
GeneOntologyCellularComponent	external encapsulating structure	A2M TPSAB1 FRAS1 RELN MATN2 DAG1 MUC5B ADAMTSL3 ITIH1 HMCN1 VCAN CSPG4 LTBP4 MUC5AC PLXNA2 TPSB2	2.68e-07	658	108	16	GO:0030312
GeneOntologyCellularComponent	collagen-containing extracellular matrix	A2M TPSAB1 FRAS1 RELN MATN2 DAG1 ITIH1 HMCN1 VCAN CSPG4 LTBP4 PLXNA2 TPSB2	3.53e-06	530	108	13	GO:0062023
GeneOntologyCellularComponent	Golgi lumen	DAG1 MUC5B APP VCAN CSPG4 MUC5AC	2.18e-05	109	108	6	GO:0005796
GeneOntologyCellularComponent	anchoring junction	FLNA FLNB DCHS2 EPPK1 ARHGEF5 DAG1 MAGI3 APP ITGAL MAST2 FAT1 HMCN1 CSPG4 ADAM17 PLEC ABCC2	4.05e-05	976	108	16	GO:0070161
GeneOntologyCellularComponent	costamere	DAG1 PLEC AHNAK2	1.92e-04	22	108	3	GO:0043034
GeneOntologyCellularComponent	cell-cell junction	FLNA DCHS2 EPPK1 DAG1 MAGI3 APP ITGAL FAT1 HMCN1 ADAM17 ABCC2	2.43e-04	591	108	11	GO:0005911
GeneOntologyCellularComponent	glycoprotein complex	FLNA DAG1 SGCZ	2.84e-04	25	108	3	GO:0090665
GeneOntologyCellularComponent	cell-substrate junction	FLNA FLNB EPPK1 DAG1 FAT1 HMCN1 CSPG4 ADAM17 PLEC	4.88e-04	443	108	9	GO:0030055
GeneOntologyCellularComponent	myofibril	FLNA FLNB PDE4D DAG1 RYR2 PLEC AHNAK2	5.45e-04	273	108	7	GO:0030016
GeneOntologyCellularComponent	dystroglycan complex	DAG1 SGCZ	5.46e-04	7	108	2	GO:0016011
GeneOntologyCellularComponent	contractile muscle fiber	FLNA FLNB PDE4D DAG1 RYR2 PLEC AHNAK2	7.77e-04	290	108	7	GO:0043292
GeneOntologyCellularComponent	Z disc	FLNA FLNB RYR2 PLEC AHNAK2	1.13e-03	151	108	5	GO:0030018
GeneOntologyCellularComponent	hemidesmosome	EPPK1 PLEC	1.41e-03	11	108	2	GO:0030056
GeneOntologyCellularComponent	I band	FLNA FLNB RYR2 PLEC AHNAK2	1.72e-03	166	108	5	GO:0031674
GeneOntologyCellularComponent	immunological synapse	SOCS6 ITGAL CARD11	2.08e-03	49	108	3	GO:0001772
HumanPheno	Broad face	FLNA FLNB PDE4D ZNF711	1.12e-05	18	42	4	HP:0000283
MousePheno	postnatal lethality	GPD2 FLNA FLNB FRAS1 RELN PDE4D XDH DBT ITGA9 TRIP13 RYR2 ZIC1 FAT1 TMTC3 ZIC5 ADAM17 PLEC LTBP4 UNC13A	1.46e-05	1084	83	19	MP:0002082
Domain	EGF-like_dom	FAT4 FRAS1 RELN PAMR1 ADAM18 MATN2 FAT1 HMCN1 MEGF8 VCAN LTBP4	2.10e-07	249	108	11	IPR000742
Domain	EGF-like_CS	FAT4 RELN PAMR1 ADAM18 MATN2 FAT1 HMCN1 MEGF8 VCAN ADAM17 LTBP4	3.35e-07	261	108	11	IPR013032
Domain	EGF_CA	FAT4 PAMR1 MATN2 FAT1 HMCN1 MEGF8 VCAN LTBP4	5.37e-07	122	108	8	SM00179
Domain	EGF-like_Ca-bd_dom	FAT4 PAMR1 MATN2 FAT1 HMCN1 MEGF8 VCAN LTBP4	6.08e-07	124	108	8	IPR001881
Domain	EGF	FAT4 FRAS1 RELN PAMR1 MATN2 FAT1 HMCN1 MEGF8 VCAN LTBP4	1.08e-06	235	108	10	SM00181
Domain	EGF_3	FAT4 RELN PAMR1 ADAM18 MATN2 FAT1 HMCN1 MEGF8 VCAN LTBP4	1.08e-06	235	108	10	PS50026
Domain	ASX_HYDROXYL	FAT4 MATN2 FAT1 HMCN1 MEGF8 VCAN LTBP4	1.83e-06	100	108	7	PS00010
Domain	EGF-type_Asp/Asn_hydroxyl_site	FAT4 MATN2 FAT1 HMCN1 MEGF8 VCAN LTBP4	2.71e-06	106	108	7	IPR000152
Domain	EGF_2	FAT4 RELN PAMR1 ADAM18 MATN2 FAT1 HMCN1 MEGF8 VCAN LTBP4	3.19e-06	265	108	10	PS01186
Domain	EGF_CA	FAT4 MATN2 FAT1 HMCN1 MEGF8 LTBP4	1.05e-05	86	108	6	PF07645
Domain	EGF_1	FAT4 RELN PAMR1 ADAM18 FAT1 HMCN1 MEGF8 VCAN LTBP4	1.73e-05	255	108	9	PS00022
Domain	SCAN	ZSCAN31 ZKSCAN7 ZKSCAN5 ZSCAN30 ZSCAN16	1.78e-05	56	108	5	SM00431
Domain	EGF_Ca-bd_CS	FAT4 FAT1 HMCN1 MEGF8 VCAN LTBP4	2.10e-05	97	108	6	IPR018097
Domain	SCAN_BOX	ZSCAN31 ZKSCAN7 ZKSCAN5 ZSCAN30 ZSCAN16	2.11e-05	58	108	5	PS50804
Domain	SCAN	ZSCAN31 ZKSCAN7 ZKSCAN5 ZSCAN30 ZSCAN16	2.11e-05	58	108	5	PF02023
Domain	SCAN_dom	ZSCAN31 ZKSCAN7 ZKSCAN5 ZSCAN30 ZSCAN16	2.11e-05	58	108	5	IPR003309
Domain	Retrov_capsid_C	ZSCAN31 ZKSCAN7 ZKSCAN5 ZSCAN30 ZSCAN16	2.30e-05	59	108	5	IPR008916
Domain	EGF_CA	FAT4 FAT1 HMCN1 MEGF8 VCAN LTBP4	2.36e-05	99	108	6	PS01187
Domain	Growth_fac_rcpt_	FAT4 FRAS1 MATN2 FAT1 HMCN1 MEGF8 LTBP4	3.41e-05	156	108	7	IPR009030
Domain	VWC_out	FRAS1 MUC5B MUC5AC	1.70e-04	19	108	3	SM00215
Domain	DUF1736	TMTC1 TMTC3	1.97e-04	4	108	2	IPR013618
Domain	DUF1736	TMTC1 TMTC3	1.97e-04	4	108	2	PF08409
Domain	ACTININ_2	FLNA FLNB PLEC	3.06e-04	23	108	3	PS00020
Domain	ACTININ_1	FLNA FLNB PLEC	3.06e-04	23	108	3	PS00019
Domain	Actinin_actin-bd_CS	FLNA FLNB PLEC	3.06e-04	23	108	3	IPR001589
Domain	-	EPPK1 PLEC	4.89e-04	6	108	2	3.90.1290.10
Domain	WxxW_domain	MUC5B MUC5AC	4.89e-04	6	108	2	IPR025155
Domain	Mucin2_WxxW	MUC5B MUC5AC	4.89e-04	6	108	2	PF13330
Domain	VWC	FRAS1 MUC5B MUC5AC	5.54e-04	28	108	3	PF00093
Domain	-	HIVEP2 ZSCAN31 ZKSCAN7 ZKSCAN5 ZIC1 ZNF711 ZNF792 ZIC5 ZSCAN30 ZSCAN16 ZNF653 ZNF639	5.56e-04	679	108	12	3.30.160.60
Domain	Tryp_SPc	TPSAB1 PAMR1 CTRC TYSND1 TPSB2	5.90e-04	117	108	5	SM00020
Domain	zf-C2H2	HIVEP2 ZSCAN31 ZKSCAN7 ZKSCAN5 ZIC1 ZNF711 ZNF792 ZIC5 ZSCAN30 ZSCAN16 ZNF653 ZNF639	6.66e-04	693	108	12	PF00096
Domain	Znf_C2H2/integrase_DNA-bd	HIVEP2 ZSCAN31 ZKSCAN7 ZKSCAN5 ZIC1 ZNF711 ZNF792 ZIC5 ZSCAN30 ZSCAN16 ZNF653 ZNF639	6.74e-04	694	108	12	IPR013087
Domain	Plectin	EPPK1 PLEC	6.83e-04	7	108	2	PF00681
Domain	Plectin_repeat	EPPK1 PLEC	6.83e-04	7	108	2	IPR001101
Domain	PLEC	EPPK1 PLEC	6.83e-04	7	108	2	SM00250
Domain	Trypsin_dom	TPSAB1 PAMR1 CTRC TYSND1 TPSB2	6.88e-04	121	108	5	IPR001254
Domain	Trypsin	TPSAB1 PAMR1 CTRC TYSND1 TPSB2	6.88e-04	121	108	5	PF00089
Domain	Peptidase_S1_PA	TPSAB1 PAMR1 CTRC TYSND1 TPSB2	7.41e-04	123	108	5	IPR009003
Domain	EGF	PAMR1 MATN2 FAT1 HMCN1 VCAN	8.26e-04	126	108	5	PF00008
Domain	MacrogloblnA2_thiol-ester-bond	A2M C3	9.07e-04	8	108	2	IPR019565
Domain	Thiol-ester_cl	A2M C3	9.07e-04	8	108	2	PF10569
Domain	MacrogloblnA2_CS	A2M C3	9.07e-04	8	108	2	IPR019742
Domain	A2M_N_2	A2M C3	9.07e-04	8	108	2	SM01359
Domain	-	A2M C3	9.07e-04	8	108	2	2.60.40.690
Domain	A2M_recep	A2M C3	9.07e-04	8	108	2	SM01361
Domain	A2M	A2M C3	9.07e-04	8	108	2	SM01360
Domain	DUF1220	NBPF4 NBPF6	1.16e-03	9	108	2	SM01148
Domain	VWFC_1	FRAS1 MUC5B MUC5AC	1.17e-03	36	108	3	PS01208
Domain	VWFA	MATN2 ITGAL ITIH1 HMCN1	1.31e-03	82	108	4	PS50234
Domain	VWFC_2	FRAS1 MUC5B MUC5AC	1.37e-03	38	108	3	PS50184
Domain	VWC	FRAS1 MUC5B MUC5AC	1.37e-03	38	108	3	SM00214
Domain	LAM_G_DOMAIN	FAT4 FAT1 CSPG4	1.37e-03	38	108	3	PS50025
Domain	VWA	MATN2 ITGAL ITIH1 HMCN1	1.43e-03	84	108	4	SM00327
Domain	IG_FLMN	FLNA FLNB	1.45e-03	10	108	2	SM00557
Domain	A2M	A2M C3	1.45e-03	10	108	2	PF00207
Domain	A2M_N_2	A2M C3	1.45e-03	10	108	2	IPR011625
Domain	A2M_comp	A2M C3	1.45e-03	10	108	2	IPR011626
Domain	A2M_recep	A2M C3	1.45e-03	10	108	2	PF07677
Domain	A2M_comp	A2M C3	1.45e-03	10	108	2	PF07678
Domain	A2M_N	A2M C3	1.45e-03	10	108	2	PF01835
Domain	A2M_N	A2M C3	1.45e-03	10	108	2	IPR002890
Domain	A-macroglobulin_rcpt-bd	A2M C3	1.45e-03	10	108	2	IPR009048
Domain	ALPHA_2_MACROGLOBULIN	A2M C3	1.45e-03	10	108	2	PS00477
Domain	A2M_N_2	A2M C3	1.45e-03	10	108	2	PF07703
Domain	Macroglobln_a2	A2M C3	1.45e-03	10	108	2	IPR001599
Domain	Laminin_G_2	FAT4 FAT1 CSPG4	1.59e-03	40	108	3	PF02210
Domain	ZINC_FINGER_C2H2_2	HIVEP2 ZSCAN31 ZKSCAN7 ZKSCAN5 ZIC1 ZNF711 ZNF792 ZIC5 ZSCAN30 ZSCAN16 ZNF653 ZNF639	1.74e-03	775	108	12	PS50157
Domain	Filamin	FLNA FLNB	1.76e-03	11	108	2	PF00630
Domain	FILAMIN_REPEAT	FLNA FLNB	1.76e-03	11	108	2	PS50194
Domain	Filamin/ABP280_rpt	FLNA FLNB	1.76e-03	11	108	2	IPR001298
Domain	Filamin/ABP280_repeat-like	FLNA FLNB	1.76e-03	11	108	2	IPR017868
Domain	DUF1220	NBPF4 NBPF6	1.76e-03	11	108	2	PF06758
Domain	NBPF_dom	NBPF4 NBPF6	1.76e-03	11	108	2	IPR010630
Domain	NBPF	NBPF4 NBPF6	1.76e-03	11	108	2	PS51316
Domain	ZINC_FINGER_C2H2_1	HIVEP2 ZSCAN31 ZKSCAN7 ZKSCAN5 ZIC1 ZNF711 ZNF792 ZIC5 ZSCAN30 ZSCAN16 ZNF653 ZNF639	1.77e-03	777	108	12	PS00028
Domain	VWF_dom	FRAS1 MUC5B MUC5AC	1.83e-03	42	108	3	IPR001007
Domain	LamG	FAT4 FAT1 CSPG4	2.10e-03	44	108	3	SM00282
Domain	C8	MUC5B MUC5AC	2.11e-03	12	108	2	PF08742
Domain	TIL	MUC5B MUC5AC	2.11e-03	12	108	2	PF01826
Domain	-	A2M C3	2.11e-03	12	108	2	1.50.10.20
Domain	Znf_C2H2-like	HIVEP2 ZSCAN31 ZKSCAN7 ZKSCAN5 ZIC1 ZNF711 ZNF792 ZIC5 ZSCAN30 ZSCAN16 ZNF653 ZNF639	2.17e-03	796	108	12	IPR015880
Domain	Znf_C2H2	HIVEP2 ZSCAN31 ZKSCAN7 ZKSCAN5 ZIC1 ZNF711 ZNF792 ZIC5 ZSCAN30 ZSCAN16 ZNF653 ZNF639	2.38e-03	805	108	12	IPR007087
Domain	ZnF_C2H2	HIVEP2 ZSCAN31 ZKSCAN7 ZKSCAN5 ZIC1 ZNF711 ZNF792 ZIC5 ZSCAN30 ZSCAN16 ZNF653 ZNF639	2.45e-03	808	108	12	SM00355
Domain	6-hairpin_glycosidase-like	PHKA2 AGL	2.48e-03	13	108	2	IPR008928
Domain	Unchr_dom_Cys-rich	MUC5B MUC5AC	2.48e-03	13	108	2	IPR014853
Domain	C8	MUC5B MUC5AC	2.48e-03	13	108	2	SM00832
Domain	VWF_A	MATN2 ITGAL ITIH1 HMCN1	2.61e-03	99	108	4	IPR002035
Domain	TIL_dom	MUC5B MUC5AC	2.88e-03	14	108	2	IPR002919
Domain	Ig_E-set	A2M FLNA FLNB PLXNA2	3.12e-03	104	108	4	IPR014756
Domain	-	DDB1 WDR59 WDR87 PAN2 WDR90 PAK1IP1 PLXNA2	3.22e-03	333	108	7	2.130.10.10
Domain	Glyco_hormone_CN	MUC5B MUC5AC	3.31e-03	15	108	2	IPR006208
Domain	Cys_knot	MUC5B MUC5AC	3.31e-03	15	108	2	PF00007
Domain	WD40/YVTN_repeat-like_dom	DDB1 WDR59 WDR87 PAN2 WDR90 PAK1IP1 PLXNA2	3.33e-03	335	108	7	IPR015943
Domain	TRYPSIN_SER	TPSAB1 PAMR1 CTRC TPSB2	3.34e-03	106	108	4	PS00135
Domain	TRYPSIN_HIS	TPSAB1 PAMR1 CTRC TPSB2	3.46e-03	107	108	4	PS00134
Domain	VWF_type-D	MUC5B MUC5AC	3.77e-03	16	108	2	IPR001846
Domain	VWFD	MUC5B MUC5AC	3.77e-03	16	108	2	PS51233
Domain	VWD	MUC5B MUC5AC	3.77e-03	16	108	2	SM00216
Domain	Integrin_alpha_C_CS	ITGA9 ITGAL	3.77e-03	16	108	2	IPR018184
Pathway	REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION	A2M TPSAB1 DAG1 APP ITGA9 ITGAL VCAN ADAM17 PLEC LTBP4	4.53e-06	300	76	10	M610
Pathway	REACTOME_DISEASES_OF_GLYCOSYLATION	DAG1 MUC5B ADAMTSL3 VCAN CSPG4 MUC5AC	1.20e-04	143	76	6	M27275
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	FLNA FRAS1 EPPK1 HIVEP2 ARFGEF2 MAST2 WDR59 FAT1 MEGF8 CSPG4 ARHGAP44 BANP WDR90 PLEC LTBP4 AHNAK2	4.67e-07	1105	111	16	35748872
Pubmed	Expression of mouse dchs1, fjx1, and fat-j suggests conservation of the planar cell polarity pathway identified in Drosophila.	DCHS2 FAT4 FAT1	1.10e-06	7	111	3	16059920
Pubmed	The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices.	FRAS1 MATN2 ITIH1 HMCN1 VCAN CSPG4 LTBP4	1.16e-06	167	111	7	22159717
Pubmed	Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function.	PDE4D TG PDE8B	1.75e-06	8	111	3	18514160
Pubmed	Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways.	FLNA FLNB PDE4D EPPK1 ARFGEF2 DDB1 VPS13D VCAN C3 PLEC MUC5AC	2.03e-06	564	111	11	21565611
Pubmed	Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate.	FLNA FLNB DAG1 UCHL3 ADAM17 PLEC	2.06e-06	116	111	6	27576135
Pubmed	Functional proteomics mapping of a human signaling pathway.	A2M FLNA FLNB ARFGEF2 DDB1 RYR2 PHKA2 NOM1 CSPG4 PLEC HDLBP	3.18e-06	591	111	11	15231748
Pubmed	A high-throughput approach for measuring temporal changes in the interactome.	FLNA FLNB PDE4D ACAT2 NPEPPS ARFGEF2 TRIP13 DDB1 AGL CIAPIN1 POP1 PLEC MVP PRRC1 GABPA AHNAK2 HDLBP	3.70e-06	1455	111	17	22863883
Pubmed	Competitive binding of E3 ligases TRIM26 and WWP2 controls SOX2 in glioblastoma.	A2M PDE4D ACAT2 NPEPPS MAST2 ITIH1 KIAA1671 NOM1 UCHL3 C3 ABCC2 PRRC1	4.07e-06	732	111	12	34732716
Pubmed	A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling.	FLNA FLNB EPPK1 PLEC	4.23e-06	34	111	4	12577067
Pubmed	Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics.	A2M MATN2 ITIH1 VCAN CSPG4 LTBP4	4.96e-06	135	111	6	28675934
Pubmed	USP9X-mediated deubiquitination of B-cell CLL/lymphoma 9 potentiates Wnt signaling and promotes breast carcinogenesis.	EPPK1 DDB1 PLEC	5.12e-06	11	111	3	31073027
Pubmed	Biochemical Reduction of the Topology of the Diverse WDR76 Protein Interactome.	FLNA FLNB FRAS1 EPPK1 DDB1 VCAN PLEC	6.95e-06	219	111	7	31353912
Pubmed	Proteome-wide identification of HSP70/HSC70 chaperone clients in human cells.	A2M GPD2 FLNA FLNB EPPK1 NPEPPS DAG1 DPYSL4 MUC5B DDB1 AGL CIAPIN1 HSD17B11 MVP AHNAK2 HDLBP	7.20e-06	1367	111	16	32687490
Pubmed	Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins.	TPSAB1 MATN2 DAG1 VCAN CSPG4 LTBP4	7.78e-06	146	111	6	27068509
Pubmed	Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan.	FLNB MACC1 PDE4D MATN2 ARHGAP44	8.09e-06	85	111	5	23648065
Pubmed	In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.	CHL1 A2M FLNA FLNB FAT4 ACAT2 NPEPPS DAG1 MUC5B ITIH1 HMCN1 MEGF8 CSPG4 C3	8.22e-06	1070	111	14	23533145
Pubmed	Cloning and analysis of cDNA encoding a major airway glycoprotein, human tracheobronchial mucin (MUC5).	MUC5B MUC5AC	1.01e-05	2	111	2	7513696
Pubmed	Analysis of axonal regeneration in the central and peripheral nervous systems of the NG2-deficient mouse.	VCAN CSPG4	1.01e-05	2	111	2	17900358
Pubmed	Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan.	VCAN CSPG4	1.01e-05	2	111	2	15609081
Pubmed	The association between MUC5AC and MUC5B genes expression and remodeling progression in severe neutrophilic asthma: A direct relationship.	MUC5B MUC5AC	1.01e-05	2	111	2	37146737
Pubmed	MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions.	MUC5B MUC5AC	1.01e-05	2	111	2	14988081
Pubmed	The structure of the human betaII-tryptase tetramer: fo(u)r better or worse.	TPSAB1 TPSB2	1.01e-05	2	111	2	10500112
Pubmed	Mucin glycosylation changes in cystic fibrosis lung disease are not manifest in submucosal gland secretions.	MUC5B MUC5AC	1.01e-05	2	111	2	15563276
Pubmed	The expression of MUC5AC and MUC5B mucin genes in the mucosa of chronic rhinosinusitis and nasal polyposis.	MUC5B MUC5AC	1.01e-05	2	111	2	17621824
Pubmed	Muc5b is required for airway defence.	MUC5B MUC5AC	1.01e-05	2	111	2	24317696
Pubmed	Macrophages are related to goblet cell hyperplasia and induce MUC5B but not MUC5AC in human bronchus epithelial cells.	MUC5B MUC5AC	1.01e-05	2	111	2	22391959
Pubmed	Plakins in development and disease.	EPPK1 PLEC	1.01e-05	2	111	2	17499243
Pubmed	Mucins MUC5AC and MUC5B Are Variably Packaged in the Same and in Separate Secretory Granules.	MUC5B MUC5AC	1.01e-05	2	111	2	35776514
Pubmed	The ocular surface phenotype of Muc5ac and Muc5b null mice.	MUC5B MUC5AC	1.01e-05	2	111	2	24327612
Pubmed	Disruption of the Flnb gene in mice phenocopies the human disease spondylocarpotarsal synostosis syndrome.	FLNA FLNB	1.01e-05	2	111	2	17635842
Pubmed	Characterization of two highly polymorphic human tryptase loci and comparison with a newly discovered monkey tryptase ortholog.	TPSAB1 TPSB2	1.01e-05	2	111	2	10898108
Pubmed	Gel-forming mucins form distinct morphologic structures in airways.	MUC5B MUC5AC	1.01e-05	2	111	2	28607090
Pubmed	Muc5b is mainly expressed and sialylated in the nasal olfactory epithelium whereas Muc5ac is exclusively expressed and fucosylated in the nasal respiratory epithelium.	MUC5B MUC5AC	1.01e-05	2	111	2	31030254
Pubmed	Overlapping expression of ARFGEF2 and Filamin A in the neuroependymal lining of the lateral ventricles: insights into the cause of periventricular heterotopia.	FLNA ARFGEF2	1.01e-05	2	111	2	16320251
Pubmed	The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium.	MUC5B MUC5AC	1.01e-05	2	111	2	23527003
Pubmed	Versican G1 and G3 domains are upregulated and latent transforming growth factor-β binding protein-4 is downregulated in breast cancer stroma.	VCAN LTBP4	1.01e-05	2	111	2	21505857
Pubmed	Up-regulation of MUC5AC and MUC5B mucin genes in nasopharyngeal respiratory mucosa and selective up-regulation of MUC5B in middle ear in pediatric otitis media with effusion.	MUC5B MUC5AC	1.01e-05	2	111	2	16540890
Pubmed	Human beta-tryptase is a ring-like tetramer with active sites facing a central pore.	TPSAB1 TPSB2	1.01e-05	2	111	2	9521329
Pubmed	Abnormalities in MUC5AC and MUC5B Protein in Airway Mucus in Asthma.	MUC5B MUC5AC	1.01e-05	2	111	2	27845589
Pubmed	Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease.	MUC5B MUC5AC	1.01e-05	2	111	2	27435107
Pubmed	Filamin depletion blocks endoplasmic spreading and destabilizes force-bearing adhesions.	FLNA FLNB	1.01e-05	2	111	2	21325628
Pubmed	Human tryptases alpha and beta/II are functionally distinct due, in part, to a single amino acid difference in one of the surface loops that forms the substrate-binding cleft.	TPSAB1 TPSB2	1.01e-05	2	111	2	10391906
Pubmed	Mucins MUC5B and MUC5AC in Distal Airways and Honeycomb Spaces: Comparison among Idiopathic Pulmonary Fibrosis/Usual Interstitial Pneumonia, Fibrotic Nonspecific Interstitial Pneumonitis, and Control Lungs.	MUC5B MUC5AC	1.01e-05	2	111	2	26871672
Pubmed	A mass spectrometric approach to study the interaction of amyloid β peptides with human α-2-macroglobulin.	A2M APP	1.01e-05	2	111	2	34478776
Pubmed	Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor.	APP ADAM17	1.01e-05	2	111	2	9774383
Pubmed	The β-amyloid peptide compromises Reelin signaling in Alzheimer's disease.	RELN APP	1.01e-05	2	111	2	27531658
Pubmed	In silico cloning of mouse Muc5b gene and upregulation of its expression in mouse asthma model.	MUC5B MUC5AC	1.01e-05	2	111	2	11587997
Pubmed	Pathophysiological relevance of sputum MUC5AC and MUC5B levels in patients with mild asthma.	MUC5B MUC5AC	1.01e-05	2	111	2	34656442
Pubmed	Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.	MUC5B MUC5AC	1.01e-05	2	111	2	34058148
Pubmed	Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease.	APP C3	1.01e-05	2	111	2	38411315
Pubmed	Amyloid precursor protein cytoplasmic domain antagonizes reelin neurite outgrowth inhibition of hippocampal neurons.	RELN APP	1.01e-05	2	111	2	17169463
Pubmed	Tumor necrosis factor alpha-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells.	ADAM17 MUC5AC	1.01e-05	2	111	2	12972643
Pubmed	Reelin signaling antagonizes beta-amyloid at the synapse.	RELN APP	1.01e-05	2	111	2	19805234
Pubmed	Characterization of a tryptase mRNA expressed in the human basophil cell line KU812.	TPSAB1 TPSB2	1.01e-05	2	111	2	8434231
Pubmed	C-Mannosylation of MUC5AC and MUC5B Cys subdomains.	MUC5B MUC5AC	1.01e-05	2	111	2	14718370
Pubmed	Limiting RyR2 Open Time Prevents Alzheimer's Disease-Related Neuronal Hyperactivity and Memory Loss but Not β-Amyloid Accumulation.	APP RYR2	1.01e-05	2	111	2	32966798
Pubmed	Cloning and characterization of a second complementary DNA for human tryptase.	TPSAB1 TPSB2	1.01e-05	2	111	2	2203827
Pubmed	Mucin production during prenatal and postnatal murine lung development.	MUC5B MUC5AC	1.01e-05	2	111	2	21653907
Pubmed	MUC5B mobilizes and MUC5AC spatially aligns mucociliary transport on human airway epithelium.	MUC5B MUC5AC	1.01e-05	2	111	2	36427316
Pubmed	Structural and functional aspects of filamins.	FLNA FLNB	1.01e-05	2	111	2	11336782
Pubmed	The variants at FLNA and FLNB contribute to the susceptibility of hypertension and stroke with differentially expressed mRNA.	FLNA FLNB	1.01e-05	2	111	2	33649519
Pubmed	The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis.	MUC5B C3	1.01e-05	2	111	2	29565179
Pubmed	Identification of new human cadherin genes using a combination of protein motif search and gene finding methods.	DCHS2 FAT4	1.01e-05	2	111	2	15003449
Pubmed	Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells?	CHL1 CSPG4	1.01e-05	2	111	2	17592550
Pubmed	Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy.	CA9 ADAM17	1.01e-05	2	111	2	26993100
Pubmed	Mucin deficiency causes functional and structural changes of the ocular surface.	MUC5B MUC5AC	1.01e-05	2	111	2	23272068
Pubmed	Younger patients with COME are more likely to have mucoid middle ear fluid containing mucin MUC5B.	MUC5B MUC5AC	1.01e-05	2	111	2	27729120
Pubmed	De novo NUF2 variant in a novel inherited bone marrow failure syndrome including microcephaly and renal hypoplasia.	MUC5B MUC5AC	1.01e-05	2	111	2	36111525
Pubmed	Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family.	TPSAB1 TPSB2	1.01e-05	2	111	2	2187193
Pubmed	Structural requirements and mechanism for heparin-dependent activation and tetramerization of human betaI- and betaII-tryptase.	TPSAB1 TPSB2	1.01e-05	2	111	2	15567416
Pubmed	The human mast cell tryptase tetramer: a fascinating riddle solved by structure.	TPSAB1 TPSB2	1.01e-05	2	111	2	10708850
Pubmed	Tryptase haplotype in mastocytosis: relationship to disease variant and diagnostic utility of total tryptase levels.	TPSAB1 TPSB2	1.01e-05	2	111	2	17449330
Pubmed	Impact of naturally forming human α/β-tryptase heterotetramers in the pathogenesis of hereditary α-tryptasemia.	TPSAB1 TPSB2	1.01e-05	2	111	2	31337736
Pubmed	Normal murine respiratory tract has its mucus concentrated in clouds based on the Muc5b mucin.	MUC5B MUC5AC	1.01e-05	2	111	2	32348677
Pubmed	Immunohistochemical study of NG2 chondroitin sulfate proteoglycan expression in the small and large intestines.	VCAN CSPG4	1.01e-05	2	111	2	16625365
Pubmed	Reassessment of the importance of mucins in determining sputum properties in cystic fibrosis.	MUC5B MUC5AC	1.01e-05	2	111	2	24332705
Pubmed	Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis.	GPD2 FLNA FLNB EPPK1 MLEC NPEPPS MUC5B DDB1 POP1 PLEC AHNAK2 HDLBP	1.09e-05	807	111	12	30575818
Pubmed	USP45 and Spindly are part of the same complex implicated in cell migration.	FLNA FLNB EPPK1 DDB1 VPS13D VCAN PLEC	1.10e-05	235	111	7	30258100
Pubmed	Smooth muscle-endothelial cell communication activates Reelin signaling and regulates lymphatic vessel formation.	RELN ITGA9 CSPG4	1.12e-05	14	111	3	22665518
Pubmed	Protein interactome reveals converging molecular pathways among autism disorders.	FLNA FLNB MAGI3 APP DDB1 WDR59 MEGF8 ARHGAP44 LTBP4 MVP	1.30e-05	560	111	10	21653829
Pubmed	Evolutionary trajectory of receptor binding specificity and promiscuity of the spike protein of SARS-CoV-2.	TG CSPG4 C3	1.40e-05	15	111	3	36305765
Pubmed	E-cadherin interactome complexity and robustness resolved by quantitative proteomics.	FLNA FLNB MACC1 DAG1 MAGI3 KIAA1671 CIAPIN1 ADAM17 PLEC HDLBP	1.40e-05	565	111	10	25468996
Pubmed	The lymphoid lineage-specific actin-uncapping protein Rltpr is essential for costimulation via CD28 and the development of regulatory T cells.	DAG1 APP ITGAL CARD11	1.45e-05	46	111	4	23793062
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	FLNB DCHS2 RELN HIVEP2 MLEC ARFGEF2 HLCS MAGI3 RIPK4 APP LRRC4 ZKSCAN5 WDR59 PLEC MVP	1.48e-05	1285	111	15	35914814
Pubmed	Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c.	PAMR1 MATN2 DAG1 VCAN C3 ADAM17 LTBP4	1.56e-05	248	111	7	24006456
Pubmed	Sequence comparison of human and mouse genes reveals a homologous block structure in the promoter regions.	CPLANE2 FLNA EPPK1 ACAT2 DAG1 RCAN3 FAT1 VCAN CSPG4 POP1 C3 RPGR PLEC ZNF639 HDLBP	1.59e-05	1293	111	15	15342556
Pubmed	Protein profile of exosomes from trabecular meshwork cells.	A2M FLNA C3 MVP	1.86e-05	49	111	4	21362503
Pubmed	Defining the human deubiquitinating enzyme interaction landscape.	FLNA FLNB HIVEP2 NPEPPS MAGI3 TYSND1 DBT TRIP13 WDR59 UCHL3 PAN2 PLEC ZNF639	2.00e-05	1005	111	13	19615732
Pubmed	Quantitative proteomic profiling of the extracellular matrix of pancreatic islets during the angiogenic switch and insulinoma progression.	RELN MATN2 ITIH1 HMCN1 LTBP4 PLXNA2	2.18e-05	175	111	6	28071719
Pubmed	Comparison of expression patterns between CREB family transcription factor OASIS and proteoglycan core protein genes during murine tooth development.	APP VCAN CSPG4	2.49e-05	18	111	3	12684764
Pubmed	Targeting the interaction of AIMP2-DX2 with HSP70 suppresses cancer development.	FLNA FLNB DBT DDB1	2.75e-05	54	111	4	31792442
Pubmed	ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1.	FAT4 FRAS1 MLEC MATN2 ARFGEF2 DAG1 APP DDB1 FAT1 TMTC3 MEGF8 CSPG4 CIAPIN1 ADAM17	2.96e-05	1201	111	14	35696571
Pubmed	Transcriptional expression of ZICs as an independent indicator of survival in gliomas.	ZIC1 ZIC5	3.02e-05	3	111	2	34475426
Pubmed	High-Mobility Group Box 1 Upregulates MUC5AC and MUC5B Expression in Primary Airway Epithelial Cells.	MUC5B MUC5AC	3.02e-05	3	111	2	29286856
Pubmed	Opposing FlnA and FlnB interactions regulate RhoA activation in guiding dynamic actin stress fiber formation and cell spreading.	FLNA FLNB	3.02e-05	3	111	2	28175289
Pubmed	Nebulized Menthol Impairs Mucociliary Clearance via TRPM8 and MUC5AC/MUC5B in Primary Airway Epithelial Cells.	MUC5B MUC5AC	3.02e-05	3	111	2	36675209
Pubmed	Mucin 5B, carbonic anhydrase 9 and claudin 18 are potential theranostic markers of gallbladder carcinoma.	CA9 MUC5B	3.02e-05	3	111	2	30565710
Pubmed	Protease-activated alpha-2-macroglobulin can inhibit amyloid formation via two distinct mechanisms.	A2M APP	3.02e-05	3	111	2	23353684
Pubmed	Human neutrophil elastase induces MUC5AC overexpression in chronic rhinosinusitis through tumour necrosis factor-α converting enzyme.	ADAM17 MUC5AC	3.02e-05	3	111	2	26881964
Interaction	LOC254896 interactions	FAT4 MAGI3 APP FAT1 CSPG4 BANP	1.13e-07	43	109	6	int:LOC254896
Interaction	ITGB1 interactions	CA9 FLNA FLNB RELN DAG1 XDH APP ITGA9 DDB1 VCAN PLEC HSD17B11	1.76e-06	400	109	12	int:ITGB1
Interaction	NPHP4 interactions	FLNA FLNB PDE4D EPPK1 DDB1 VPS13D RPGR PLEC MUC5AC	5.49e-06	236	109	9	int:NPHP4
Interaction	LGALS1 interactions	CA9 CHL1 FLNA FAT4 FRAS1 DAG1 ITGA9 VCAN CSPG4 PLXNA2	1.30e-05	332	109	10	int:LGALS1
Interaction	ANKS4B interactions	APP BANP PLEC	1.80e-05	10	109	3	int:ANKS4B
Interaction	AGR2 interactions	GPD2 FLNA FLNB EPPK1 MLEC NPEPPS DAG1 MUC5B APP DDB1 POP1 C3 PLEC MUC5AC AHNAK2 HDLBP	4.15e-05	934	109	16	int:AGR2
GeneFamily	Zinc fingers C2H2-type\|ZF class homeoboxes and pseudogenes	HIVEP2 ZSCAN31 ZKSCAN7 ZKSCAN5 ZIC1 ZNF711 ZNF792 ZIC5 ZSCAN30 ZSCAN16 ZNF653 ZNF639	3.21e-05	718	74	12	28
GeneFamily	Cadherin related	DCHS2 FAT4 FAT1	4.29e-05	17	74	3	24
GeneFamily	Neuroblastoma breakpoint family	NBPF4 NBPF6 NBPF5P	1.10e-04	23	74	3	662
GeneFamily	EF-hand domain containing\|Plakins	EPPK1 PLEC	4.55e-04	8	74	2	939
GeneFamily	C3 and PZP like, alpha-2-macroglobulin domain containing	A2M C3	5.84e-04	9	74	2	1234
GeneFamily	CD molecules\|Integrin alpha subunits	ITGA9 ITGAL	2.42e-03	18	74	2	1160
GeneFamily	CD molecules\|Mucins	MUC5B MUC5AC	3.30e-03	21	74	2	648
GeneFamily	PDZ domain containing	MAGI3 MAST2 CARD11 AHNAK2	3.50e-03	152	74	4	1220
GeneFamily	Blood group antigens\|CD molecules\|I-set domain containing\|Immunoglobulin like domain containing	CHL1 ADAMTSL3 LRRC4 HMCN1	4.30e-03	161	74	4	593
GeneFamily	Phosphodiesterases	PDE4D PDE8B	4.30e-03	24	74	2	681
GeneFamily	Calcium voltage-gated channel subunits\|Membrane associated guanylate kinases	MAGI3 CARD11	5.04e-03	26	74	2	904
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	ADAM18 ADAM17	5.43e-03	27	74	2	47
Coexpression	NABA_MATRISOME	A2M FRAS1 RELN PAMR1 ADAM18 MATN2 MUC5B ADAMTSL3 ITIH1 HMCN1 MEGF8 VCAN CSPG4 ADAM17 LTBP4 MUC5AC PLXNA2	9.00e-07	1008	109	17	MM17056
Coexpression	NABA_MATRISOME	A2M FRAS1 RELN PAMR1 ADAM18 MATN2 MUC5B ADAMTSL3 ITIH1 HMCN1 MEGF8 VCAN CSPG4 ADAM17 LTBP4 MUC5AC PLXNA2	1.15e-06	1026	109	17	M5889
Coexpression	AIZARANI_LIVER_C29_MVECS_2	FNIP2 A2M FLNB MATN2 APP TMTC1 RPGR PLEC LTBP4	6.60e-06	313	109	9	M39128
ToppCell	COVID-19-Heart-EC_2\|Heart / Disease (COVID-19 only), tissue and cell type	A2M FLNB FAT4 PDE4D ITGA9 KIAA1671 TMTC1 RPGR PLXNA2	9.87e-10	187	110	9	40ffc06a3e3251d9b12da390210d3e045af7537a
ToppCell	facs-Lung-nan\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PAMR1 MATN2 DAG1 XDH APP ITGA9 VCAN C3 LTBP4	1.49e-09	196	110	9	b05f77f3990b662682ffeaf0e4c2fb190e0a6e65
ToppCell	facs-Lung-nan-3m\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PAMR1 MATN2 DAG1 XDH APP ITGA9 VCAN C3 LTBP4	1.49e-09	196	110	9	787c6cd92035e0b1108c2c086c42a229016e476b
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M FAT4 FRAS1 RELN MUC5B RYR2 FAT1 HMCN1	1.93e-08	184	110	8	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M FAT4 FRAS1 RELN MUC5B RYR2 FAT1 HMCN1	1.93e-08	184	110	8	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M FAT4 FRAS1 RELN MUC5B RYR2 FAT1 HMCN1	1.93e-08	184	110	8	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	LA-09._Endothelium_I\|LA / Chamber and Cluster_Paper	A2M FLNB ITGA9 KIAA1671 TMTC1 HMCN1 RPGR PLXNA2	3.28e-08	197	110	8	ab6d1ab586a188597a39854ef980b8955ebcc645
ToppCell	Control_saline-Mesenchymal_myocytic-Myofibroblastic-MatrixFB_->_Myofibroblast\|Control_saline / Treatment groups by lineage, cell group, cell type	FAT4 PAMR1 MATN2 ITGA9 ADAMTSL3 FAT1 VCAN LTBP4	3.68e-08	200	110	8	a799fc7bb83ad0524362cb5010df949741fb7bf3
ToppCell	5'-Adult-LargeIntestine-Mesenchymal-fibroblastic-Stromal_1_(ADAMDEC1+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CHL1 A2M FAT4 PDE4D MATN2 VCAN LTBP4	2.14e-07	169	110	7	c0824a93674e2bff0f09b2d2fab5bab016a2e379
ToppCell	E18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-Mesothelial\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CA9 CHL1 FRAS1 PAMR1 C3 LTBP4 AHNAK2	3.04e-07	178	110	7	bcbdd45a2307f8aea14122fa0144b96b1f6eec48
ToppCell	E18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-Mesothelial-Mesothelial_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CA9 CHL1 FRAS1 PAMR1 C3 LTBP4 AHNAK2	3.04e-07	178	110	7	c413861148129be1ee94f2ceb5999840217eebe5
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM2_(12)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	FLNA SPSB1 MATN2 ITGA9 SGCZ TMTC1 PLXNA2	3.67e-07	183	110	7	e84539978ab4de42e19186aed00f24bb50cbc21f
ToppCell	5'-Adult-LargeIntestine-Mesenchymal-myocytic-myofibroblast\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CHL1 A2M FLNA FAT4 PDE4D ITGA9 VCAN	3.67e-07	183	110	7	af8d86f15a549064530d94bd47081daf59d58ecd
ToppCell	LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MACC1 FRAS1 MAGI3 RIPK4 ITGA9 ARHGAP44 C3	3.81e-07	184	110	7	42ce855b4f8475a8298192feec785bdc69bc5bb0
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MACC1 FRAS1 MAGI3 RIPK4 ITGA9 ARHGAP44 C3	4.10e-07	186	110	7	4e94158db52df41d71e67b02b9895a358eebee0f
ToppCell	LV-10._Endothelium_II\|World / Chamber and Cluster_Paper	FLNB ZSCAN31 ITGA9 KIAA1671 TMTC1 HMCN1 PLXNA2	4.25e-07	187	110	7	7876dcb4800c2e54874df3d933efb79307a64a97
ToppCell	LPS_only-Epithelial_alveolar-AT_1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MACC1 FRAS1 MAGI3 RIPK4 ITGA9 ARHGAP44 C3	4.25e-07	187	110	7	ff26a533d310126521efe1d05cf8b9d32e524550
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM2_(12)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	FLNA SPSB1 MATN2 ITGA9 SGCZ TMTC1 PLXNA2	4.40e-07	188	110	7	3004e961d214919e08c7cd5f10c3de5cf85b35a3
ToppCell	RA-10._Endothelium_II\|World / Chamber and Cluster_Paper	FLNB ITGA9 KIAA1671 TMTC1 HMCN1 VCAN PLXNA2	4.56e-07	189	110	7	75c248b9de5e2fb7a0baa8cdbab516e575cc4394
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_lymph_vessel-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	RELN APP ITGA9 KIAA1671 TMTC1 HMCN1 RPGR	4.73e-07	190	110	7	6e6ce6dd549d1c38cfef5b3f8be06ab01ce344b7
ToppCell	RA-09._Endothelium_I\|World / Chamber and Cluster_Paper	A2M FLNB APP KIAA1671 TMTC1 RPGR PLXNA2	4.90e-07	191	110	7	c8a0c2af119bc34a8f694a7d30642f28002c84b9
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	A2M SPSB1 MATN2 ITGA9 ADAMTSL3 TMTC1 LTBP4	5.07e-07	192	110	7	bc84b9ce01b4d826a682842ab8a395dac9b91183
ToppCell	RA-09._Endothelium_I\|RA / Chamber and Cluster_Paper	A2M FLNB APP KIAA1671 TMTC1 RPGR PLXNA2	5.07e-07	192	110	7	8a1b1c3e83a68ad74f8f4eb00455c9e41aa57cfc
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	A2M SPSB1 MATN2 ITGA9 ADAMTSL3 TMTC1 LTBP4	5.07e-07	192	110	7	0ab1176cfbb0de8dd1f22c6e2c41265cf6c10ee1
ToppCell	5'-Adult-LargeIntestine-Mesenchymal-myocytic\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CHL1 A2M FLNA FAT4 PDE4D ITGA9 AHNAK2	5.25e-07	193	110	7	146e8c148478ab61b1c1dbaf1ee98a8cd4a0ff8a
ToppCell	RV-09._Endothelium_I\|RV / Chamber and Cluster_Paper	A2M FLNB KIAA1671 TMTC1 HMCN1 RPGR PLXNA2	5.44e-07	194	110	7	7b408096e717f2327c12aea35a8d5fc4621d3b06
ToppCell	RA\|World / Chamber and Cluster_Paper	FRAS1 PDE4D HIVEP2 ADAMTSL3 FAT1 PDE8B VCAN	5.44e-07	194	110	7	08f0afbb68a63150fbe107a5337299081c3f69e4
ToppCell	LPS_anti-TNF-Mesenchymal_myocytic-Myofibroblastic-MatrixFB_->_Myofibroblast\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	FLNA FAT4 PAMR1 MATN2 ITGA9 FAT1 LTBP4	6.45e-07	199	110	7	38cfd367ee8c074c11ba54edeb7a001e375e2687
ToppCell	kidney_cells-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	FLNA MATN2 APP VPS13D FAT1 VCAN PLXNA2	6.45e-07	199	110	7	174f6013af6eafa577f84205a62927f2b367fda3
ToppCell	Control_saline-Mesenchymal_myocytic-Myofibroblastic\|Control_saline / Treatment groups by lineage, cell group, cell type	FLNA PAMR1 ITGA9 RYR2 FAT1 VCAN LTBP4	6.67e-07	200	110	7	9d5b3c2dcfa55d50acc2ce2c319d51aa525d4cd1
ToppCell	Control_saline-Mesenchymal_myocytic\|Control_saline / Treatment groups by lineage, cell group, cell type	FLNA PAMR1 ADAMTSL3 RYR2 FAT1 VCAN CSPG4	6.67e-07	200	110	7	5ed4261157cd51109b314818133ac3a0d34ee5fa
ToppCell	Control_saline-Mesenchymal_myocytic-Pericyte-Pericyte_2\|Control_saline / Treatment groups by lineage, cell group, cell type	MATN2 ADAMTSL3 RYR2 FAT1 PDE8B CSPG4 CARD11	6.67e-07	200	110	7	bc8949eb34482aca166c4602ff6ab876cb4c2c3c
ToppCell	facs-Marrow-B-cells-24m-Myeloid-granulocyte_monocyte_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHL1 FRAS1 PDE4D RYR2 HMCN1 VCAN	3.47e-06	165	110	6	6d315e0734079ad05336cc2c3f24d870c9105bc8
ToppCell	facs-Marrow-B-cells-24m-Myeloid-granulocyte_monocyte_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHL1 FRAS1 PDE4D RYR2 HMCN1 VCAN	3.47e-06	165	110	6	84f5597b1bb75f42de9a224196bb8ac198bbe3bf
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D231\|Adult / Lineage, Cell type, age group and donor	FNIP2 FRAS1 MAGI3 ITGA9 FAT1 HSD17B11	4.12e-06	170	110	6	269dee5abca9f6aa079f116f0d8f1d198604d9d4
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PAMR1 SPSB1 ADAMTSL3 VCAN C3 LTBP4	4.26e-06	171	110	6	5d31fc9b60329d4ae3c77e4ca679359d9314397d
ToppCell	metastatic_Lymph_Node-Myeloid_cells-Microglia/Mac\|metastatic_Lymph_Node / Location, Cell class and cell subclass	A2M ITGA9 ZKSCAN5 MEGF8 C3 MUC5AC	4.41e-06	172	110	6	f673a2e697b46e7cfa4186cb3fb2b98e3c83703e
ToppCell	Adult-Epithelial-lung_goblet_cell-D231\|Adult / Lineage, Cell type, age group and donor	CHL1 DCHS2 FRAS1 MUC5B PDE8B MUC5AC	4.71e-06	174	110	6	7d2f802f493f19a068e097b2909a9000e2160266
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	A2M FLNA RYR2 TMTC1 CSPG4 UNC13A	4.87e-06	175	110	6	316f2ea930437bf1243b1c0f45e6bd864112c6f2
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	A2M FLNA RYR2 TMTC1 CSPG4 UNC13A	4.87e-06	175	110	6	a9f08e1e4c2997dcdd3e5d92daac480da19100b8
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PAMR1 ADAMTSL3 RYR2 VCAN C3 LTBP4	5.20e-06	177	110	6	9ec7f1e64312d26d434b3312b58386715dbad644
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PAMR1 ADAMTSL3 RYR2 VCAN C3 LTBP4	5.20e-06	177	110	6	016277dfd59b1793fddaaadc2b3f41622d76ce3a
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MACC1 FRAS1 MAGI3 RIPK4 ITGA9 ARHGAP44	5.54e-06	179	110	6	04ce3673e46606f63d9c87bcba3a64c96817d812
ToppCell	COVID-19-Heart-EC_2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	A2M FLNB FAT4 ITGA9 TMTC1 RPGR	5.54e-06	179	110	6	2a53d94f6c30bf887dfe88f1693ea057218c852d
ToppCell	Control-Epithelial_cells-Airway_club\|Control / group, cell type (main and fine annotations)	CHL1 FNIP2 MACC1 PDE4D MAGI3 ITGA9	5.91e-06	181	110	6	c755d23dd9aabc717dc73e2b3fa99a1f751e6507
ToppCell	Children_(3_yrs)-Epithelial-club_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	FLNB FRAS1 XDH MAGI3 ITGA9 FAT1	6.10e-06	182	110	6	215c303df42f13597b2c7a95cb157c6bc7aca9a1
ToppCell	droplet-Heart-HEART_(LV+RV_ONLY)-30m-Neuronal-cardiac_neuron\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHL1 RELN LRRC4 SGCZ CSPG4 TREML1	6.29e-06	183	110	6	876b4f128c2168fdae7488201ff44f19c06c8415
ToppCell	COVID-19-Epithelial_cells-ECM-high_epithelial\|COVID-19 / group, cell type (main and fine annotations)	A2M FLNB PDE4D MAGI3 ARHGAP44 PLXNA2	6.29e-06	183	110	6	dc1d380bf7564f290256cb7108063d1bd2da732b
ToppCell	droplet-Heart-HEART_(LV+RV_ONLY)-30m-Neuronal\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHL1 RELN LRRC4 SGCZ CSPG4 TREML1	6.29e-06	183	110	6	b190b650e61b1b20baf5e42d04acac82d3fd1400
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Outer_Medullary_Collecting_Duct_Principal_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	MACC1 FRAS1 PDE4D ADAMTSL3 SGCZ ARHGAP44	6.29e-06	183	110	6	b5ede5a0048c585b73c00e88aeddbcaf669347b1
ToppCell	droplet-Heart-HEART_(LV+RV_ONLY)-30m-Neuronal-cardiac_neuron\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHL1 RELN MATN2 LRRC4 SGCZ CSPG4	6.29e-06	183	110	6	8330c39184ce076e1f95fd3725b68af551d89db0
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PAMR1 MATN2 ITGA9 SGCZ LTBP4 AHNAK2	6.70e-06	185	110	6	6712512100ccef456d2e2bd201d0987986c92ac9
ToppCell	Control-Epithelial_alveolar-AT_2-Differentiating_AT2\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MACC1 MAGI3 ITGA9 ARHGAP44 C3 PLXNA2	6.70e-06	185	110	6	0d2add28ac1f4fa6de7699be009bf8391badaf4c
ToppCell	COVID-19-Neuronal_cells-Neuronal_cells\|COVID-19 / group, cell type (main and fine annotations)	RELN APP ITGA9 ADAMTSL3 KIAA1671 RPGR	6.70e-06	185	110	6	4a095829992b39856a73bdfac03ee68b9aa0d3b8
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PAMR1 MATN2 ITGA9 ADAMTSL3 SGCZ LTBP4	6.70e-06	185	110	6	3b2dfc8f4c87be516265dbecfc251276034d0efd
ToppCell	COVID-19-Neuronal_cells\|COVID-19 / group, cell type (main and fine annotations)	RELN APP ITGA9 ADAMTSL3 KIAA1671 RPGR	6.70e-06	185	110	6	36ce23893915f5c380cca39b2c33a516edf31c3a
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_artery-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	FLNB FAT4 TMTC1 HMCN1 RPGR PLXNA2	6.70e-06	185	110	6	a7ae76058b2082020cadec49d63b9f4e24d21734
ToppCell	LPS_only-Epithelial_alveolar\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MACC1 RIPK4 ITGA9 SGCZ ARHGAP44 C3	6.90e-06	186	110	6	e0a2ea4b46af742bc7c9b2072bb85e27d5c92712
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro2_(5)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	CHL1 FAT4 MATN2 RYR2 VCAN LTBP4	6.90e-06	186	110	6	7def03dd856b765bd3f493288641981c4f7fd26e
ToppCell	3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes-Pericytes_L.2.3.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	A2M ADAMTSL3 RYR2 FAT1 PDE8B CSPG4	6.90e-06	186	110	6	888e85a025bd982d36c910db0f5a3385b1ca3b28
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MACC1 ITGA9 SGCZ ARHGAP44 C3 PLXNA2	6.90e-06	186	110	6	e83718fabb057100835d3357df407f283d23fe16
ToppCell	droplet-Heart-HEART-1m-Neuronal-nan\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHL1 RELN MATN2 DPYSL4 TG TREML1	6.90e-06	186	110	6	fddc6b93f98b10aaf8d4ebc142b46d8213f3129d
ToppCell	Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)\|World / Lineage, Cell type, age group and donor	FNIP2 MACC1 PDE4D MAGI3 ITGA9 HSD17B11	7.12e-06	187	110	6	81cc8435b2704a9a8287b3f54acaae0f11dd4ac7
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MACC1 FRAS1 MAGI3 ITGA9 ARHGAP44 C3	7.12e-06	187	110	6	58d48128547ee3513d0bf7f78e61b76b1c472ca9
ToppCell	droplet-Bladder-Unstain-18m-Epithelial-bladder_mesenchymal_cell_(Scara5+)\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SPSB1 MATN2 XDH ADAMTSL3 C3 LTBP4	7.12e-06	187	110	6	7beba2a5d5978f2ae7d8bde10815705cf2572211
ToppCell	droplet-Lung-1m-Endothelial-lymphatic_endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CPLANE2 RELN SPSB1 KIAA1671 TMTC1 LTBP4	7.34e-06	188	110	6	dc52dd2957be3f40001f0a56f3d9ac9d66ea466e
ToppCell	droplet-Lung-1m-Endothelial-lymphatic_endothelial\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CPLANE2 RELN SPSB1 KIAA1671 TMTC1 LTBP4	7.34e-06	188	110	6	2ef08313087e91985bcffc46c3798470cdeec49c
ToppCell	droplet-Lung-1m-Endothelial-lymphatic_endothelial-lymphatic_endothelial_cell\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CPLANE2 RELN SPSB1 KIAA1671 TMTC1 LTBP4	7.34e-06	188	110	6	1f1604b6dc0a8ad0be3d9aac0bef448459c22465
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_lymph_vessel-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	RELN APP ITGA9 KIAA1671 TMTC1 HMCN1	7.34e-06	188	110	6	2db80767903703e7e0a1a37c598f7877a909ee94
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_lymph_vessel-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	FLNB RELN APP ITGA9 KIAA1671 TMTC1	7.34e-06	188	110	6	aeecbc057dc823f8fcea8a98f18d213bacc7f4db
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	A2M DCHS2 MATN2 TMTC1 VCAN LTBP4	7.57e-06	189	110	6	71397e993a77d70b2eeede240bdfc7660b558987
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_myocytic\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	FLNA SPSB1 MATN2 TMTC1 PLXNA2 AHNAK2	7.57e-06	189	110	6	b6d5dec55bf352f6ae19d8f488ae70aa10fb9a8f
ToppCell	RA-14._Fibroblast_III\|RA / Chamber and Cluster_Paper	HIVEP2 SPSB1 FAT1 VCAN BANP C3	7.57e-06	189	110	6	46e9a58aacd79db5a02898a8c7244e1884adcfd1
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	A2M DCHS2 MATN2 TMTC1 VCAN LTBP4	7.57e-06	189	110	6	4eea4759520c312bd17a681034d8074e47093d2b
ToppCell	RA-10._Endothelium_II\|RA / Chamber and Cluster_Paper	FLNB ITGA9 KIAA1671 TMTC1 HMCN1 PLXNA2	7.57e-06	189	110	6	c81787a8c662db5d7814c583dd64562857629e81
ToppCell	LPS-IL1RA-Endothelial-Endothelial-Artery\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FLNB ITGA9 KIAA1671 TMTC1 HMCN1 LTBP4	7.80e-06	190	110	6	aed65d584ca0c25f6a8313c66b421a6618af82ea
ToppCell	COVID-19-kidney-AQP1+SLC14A1+EC\|kidney / Disease (COVID-19 only), tissue and cell type	A2M FAT4 ITGA9 TMTC1 RPGR PLXNA2	7.80e-06	190	110	6	1519f34d31fe0817184c5865a0bc9f0cb479b1a4
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-bronchial_goblet_cell-Goblet_(bronchial)\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CHL1 MUC5B PDE8B C3 MUC5AC HDLBP	7.80e-06	190	110	6	23f2ac4da431211084bb6ab0494c2e0b69547cb6
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_2_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PAMR1 SPSB1 MATN2 VCAN C3 LTBP4	7.80e-06	190	110	6	0fea33f2dc1efa23aaa2da1c318482a52a313ff1
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-bronchial_goblet_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CHL1 MUC5B PDE8B C3 MUC5AC HDLBP	7.80e-06	190	110	6	3c337374d89e69cc0a78e65a4a7e21db7b050fcd
ToppCell	PND07-28-samps-Mesenchymal-Myofibroblast\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	PAMR1 ITGA9 TMTC1 TMTC3 HMCN1 LTBP4	8.03e-06	191	110	6	9bbafdf316c1fa3a9f1ee30d41dd7158b5c97279
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	A2M SPSB1 ITGA9 TMTC1 VCAN LTBP4	8.03e-06	191	110	6	39092a0aff8097617820c59f5fea9ee2bb4f63a2
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	A2M FLNA RYR2 TMTC1 CSPG4 UNC13A	8.03e-06	191	110	6	04c4d454b57e29a8d1dcdeb4678ce71bdc29b77b
ToppCell	LPS-antiTNF-Endothelial-Endothelial-Artery\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FLNB FAT4 KIAA1671 TMTC1 HMCN1 LTBP4	8.03e-06	191	110	6	4b3d5157344dbfbf4fab518611cd9fa37fac7bd9
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	A2M FAT4 FRAS1 ADAMTSL3 RYR2 HMCN1	8.03e-06	191	110	6	6688cee34beee4f151ac17fccbc9c26a9aad72e1
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	A2M SPSB1 ITGA9 TMTC1 VCAN LTBP4	8.03e-06	191	110	6	ee5f1b1c59029c46cbb1a00935c03b9317bb9da9
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	A2M MATN2 ADAMTSL3 TMTC1 VCAN LTBP4	8.28e-06	192	110	6	5105e4b577408b4e1a62d0a44c23c2b830ccad88
ToppCell	3'-Distal_airway-Mesenchymal-Fibroblastic-fibroblastic_type_1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	A2M PAMR1 SPSB1 MATN2 C3 LTBP4	8.28e-06	192	110	6	a8b7c539dc3037071bf068f372e4215563e11de4
ToppCell	PND10-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1-AT1_mature\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	FRAS1 DAG1 MAGI3 APP PDE8B ARHGAP44	8.28e-06	192	110	6	790282d4232311df3dac4ad97c80fc53443beccc
ToppCell	PND10-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	FRAS1 DAG1 MAGI3 APP PDE8B ARHGAP44	8.28e-06	192	110	6	b2d9bffccd6264b4f12d88a0780646ee0b41969f
ToppCell	3'-Distal_airway-Mesenchymal-Fibroblastic\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	A2M PAMR1 SPSB1 MATN2 C3 LTBP4	8.28e-06	192	110	6	2143e1fad2e88b90d668e12af37b2092d379090f
ToppCell	3'-Distal_airway-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	A2M PAMR1 SPSB1 MATN2 C3 LTBP4	8.28e-06	192	110	6	904c003c4f73b1dfc8243cee02aad2676c515e50
ToppCell	COPD-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	A2M FRAS1 PDE4D RYR2 HMCN1 PLXNA2	8.28e-06	192	110	6	62904f94dfce430456f05066522cbf9bd29f4d7e
ToppCell	RV-10._Endothelium_II\|RV / Chamber and Cluster_Paper	FLNB ITGA9 KIAA1671 TMTC1 HMCN1 PLXNA2	8.53e-06	193	110	6	01c2df9206f1527c578e808978e58196c35e72f5
ToppCell	human_hepatoblastoma-Tumor_cells\|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)	FLNB FRAS1 ARFGEF2 MAGI3 WDR59 ABCC2	8.53e-06	193	110	6	503a979328c68b096680b71359a26f02fafdff35
ToppCell	RV-10._Endothelium_II\|World / Chamber and Cluster_Paper	FLNB ITGA9 KIAA1671 TMTC1 HMCN1 PLXNA2	8.53e-06	193	110	6	2531266bc57339d4e2b22a88817008e32b8c1598
ToppCell	RV-09._Endothelium_I\|World / Chamber and Cluster_Paper	A2M KIAA1671 TMTC1 HMCN1 RPGR PLXNA2	8.53e-06	193	110	6	e3fa47e2c7cd8a5b69186711c57751f2296de8ae
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	PAMR1 MATN2 ADAMTSL3 TMTC1 C3 LTBP4	8.78e-06	194	110	6	c49f72441b3557e2c3a9c4239e68c0cf0652814b
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	A2M SPSB1 MATN2 TMTC1 VCAN LTBP4	8.78e-06	194	110	6	cf0244a29934e515446ac917d3c30672b460fb04
ToppCell	LV-10._Endothelium_II\|LV / Chamber and Cluster_Paper	FLNB ITGA9 KIAA1671 TMTC1 HMCN1 PLXNA2	8.78e-06	194	110	6	b6cc849fa08599bff9839ef382d190cc964e273e
Drug	Aminophylline [317-34-0]; Down 200; 9.6uM; MCF7; HT_HG-U133A	HLCS MUC5B RCAN3 VPS13D C3 ADAM17 RPGR LTBP4 ZNF639 AHNAK2	3.95e-08	196	110	10	3374_DN
Drug	(-) -Levobunolol hydrochloride [27912-14-7]; Down 200; 12.2uM; PC3; HT_HG-U133A	PDE4D SPSB1 APP ITGAL MAST2 RYR2 GLE1 PDE8B UNC13A	5.39e-07	199	110	9	4016_DN
Drug	TAPI-2	APP ADAM17 MUC5AC	3.79e-06	7	110	3	ctd:C099410
Drug	Tiaprofenic acid [33005-95-7]; Down 200; 15.4uM; MCF7; HT_HG-U133A	GLS2 SPSB1 DPYSL4 GLE1 RPGR MVP ZNF639 HDLBP	4.87e-06	195	110	8	2852_DN
Drug	Flurbiprofen [5104-49-4]; Down 200; 16.4uM; HL60; HT_HG-U133A	GPD2 HLCS DBT ZKSCAN5 WDR59 CSPG4 ARHGAP44 ABCC2	5.06e-06	196	110	8	3095_DN
Drug	AC1L8VEV	TPSAB1 PLEC MUC5AC TPSB2	5.09e-06	24	110	4	CID000433433
Drug	Acetaminophen [103-90-2]; Down 200; 26.4uM; MCF7; HT_HG-U133A	EPPK1 HIVEP2 HLCS DAG1 MAST2 C3 ADAM17 AHNAK2	5.25e-06	197	110	8	3364_DN
Drug	Etodolac [41340-25-4]; Up 200; 14uM; PC3; HT_HG-U133A	FAT4 ZSCAN31 ARFGEF2 SOCS6 MAST2 ZKSCAN5 WDR59 VPS13D	5.25e-06	197	110	8	2091_UP
Drug	Ifenprodil tartrate [23210-58-4]; Down 200; 8.4uM; PC3; HT_HG-U133A	EPPK1 SPSB1 MUC5B ZKSCAN5 ZNF711 VCAN ADAM17 RPGR	5.25e-06	197	110	8	5044_DN
Drug	Merbromin [129-16-8]; Up 200; 5uM; HL60; HT_HG-U133A	A2M GPD2 DBT APP WDR59 VCAN ADAM17 MVP	5.45e-06	198	110	8	2577_UP
Drug	Niridazole [61-57-4]; Down 200; 18.6uM; PC3; HT_HG-U133A	FAT4 GLS2 DAG1 DBT MAST2 VPS13D PDE8B VCAN	5.45e-06	198	110	8	4621_DN
Drug	Convolamine hydrochloride [500-56-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A	ZSCAN31 HLCS APP ZKSCAN5 PHKA2 VPS13D MVP ZNF639	5.45e-06	198	110	8	2771_DN
Drug	Vitexin [3681-93-4]; Up 200; 9.2uM; PC3; HT_HG-U133A	GLS2 CTRC HLCS ITGAL RYR2 ZNF711 VCAN LTBP4	5.87e-06	200	110	8	4588_UP
Drug	Leupeptin hydrochloride	A2M TPSAB1 CTRC APP TG UCHL3 C3 TPSB2 HDLBP	7.92e-06	276	110	9	CID000003910
Drug	Hexetidine [141-94-6]; Down 200; 11.8uM; MCF7; HT_HG-U133A	HLCS DPYSL4 SOCS6 MAST2 VPS13D C3 AHNAK2	4.16e-05	192	110	7	3318_DN
Drug	NPGB	TPSAB1 CTRC C3 TPSB2	4.55e-05	41	110	4	CID000030744
Drug	Amethopterin (R,S) [59-05-2]; Down 200; 8.8uM; PC3; HT_HG-U133A	FAT4 GLS2 HLCS ZKSCAN5 RYR2 VCAN MVP	4.59e-05	195	110	7	6654_DN
Drug	Troleandomycin [2751-09-9]; Down 200; 5uM; MCF7; HT_HG-U133A	HIVEP2 SPSB1 DBT APP ADAM17 HSD17B11 HDLBP	4.74e-05	196	110	7	1465_DN
Drug	Flumethasone [2135-17-3]; Up 200; 9.8uM; MCF7; HT_HG-U133A	DPYSL4 SOCS6 WDR59 PLEC LTBP4 MVP ZNF639	4.74e-05	196	110	7	3410_UP
Drug	Brinzolamide [138890-62-7]; Down 200; 10.4uM; MCF7; HT_HG-U133A	GPD2 HLCS APP MAST2 RYR2 PDE8B ZNF639	4.74e-05	196	110	7	5016_DN
Drug	Fluoxetine hydrochloride [59333-67-4]; Down 200; 11.6uM; PC3; HT_HG-U133A	HLCS DAG1 DBT APP VPS13D GLE1 PDE8B	4.74e-05	196	110	7	6757_DN
Drug	Sotalol hydrochloride [959-24-0]; Down 200; 13uM; MCF7; HT_HG-U133A	HLCS XDH VPS13D PDE8B MVP PLXNA2 AHNAK2	4.90e-05	197	110	7	4160_DN
Drug	Verapamyl hydrochloride [152-11-4]; Down 200; 8.2uM; MCF7; HT_HG-U133A	HIVEP2 GLS2 HLCS DBT APP RYR2 VPS13D	4.90e-05	197	110	7	5387_DN
Drug	Sulmazole [73384-60-8]; Down 200; 14uM; MCF7; HT_HG-U133A	A2M SPSB1 HLCS XDH PDE8B ABCC2 LTBP4	4.90e-05	197	110	7	4127_DN
Drug	Methyldopate hydrochloride [2508-79-4]; Down 200; 14.6uM; MCF7; HT_HG-U133A	GPD2 SPSB1 APP RCAN3 RYR2 VPS13D ZNF639	4.90e-05	197	110	7	4986_DN
Drug	clozapine; Down 200; 10uM; MCF7; HT_HG-U133A	HLCS ADAMTSL3 PDE8B LTBP4 MUC5AC ZNF639 AHNAK2	4.90e-05	197	110	7	5589_DN
Drug	Dihydrostreptomycin sulfate [5490-27-7]; Up 200; 2.8uM; PC3; HT_HG-U133A	CA9 PDE4D MUC5B MAST2 VPS13D MEGF8 ZNF639	4.90e-05	197	110	7	5751_UP
Drug	Trimethoprim [738-70-5]; Down 200; 13.8uM; HL60; HT_HG-U133A	SOCS6 DBT APP VPS13D GLE1 VCAN PLEC	5.05e-05	198	110	7	2345_DN
Drug	Trapidil [15421-84-8]; Up 200; 19.4uM; MCF7; HT_HG-U133A	DPYSL4 XDH RCAN3 RYR2 VPS13D HSD17B11 MVP	5.05e-05	198	110	7	7475_UP
Drug	Acenocoumarol [152-72-7]; Down 200; 11.4uM; PC3; HT_HG-U133A	PDE4D DAG1 DBT APP RYR2 VPS13D MVP	5.05e-05	198	110	7	5878_DN
Drug	Zidovudine, AZT [30516-87-1]; Up 200; 15uM; MCF7; HT_HG-U133A	HLCS XDH MUC5B ZNF711 VPS13D VCAN C3	5.05e-05	198	110	7	3211_UP
Drug	Buflomedil hydrochloride [35543-24-9]; Up 200; 11.6uM; MCF7; HT_HG-U133A	HLCS SOCS6 ITGA9 RYR2 C3 ABCC2 HSD17B11	5.22e-05	199	110	7	3274_UP
Drug	Isopyrin hydrochloride [18342-39-7]; Up 200; 14.2uM; PC3; HT_HG-U133A	FAT4 GLS2 ADAMTSL3 GLE1 VCAN C3 PLXNA2	5.22e-05	199	110	7	5879_UP
Drug	Isocarboxazid [59-63-2]; Down 200; 17.2uM; PC3; HT_HG-U133A	PDE4D DAG1 MUC5B GLE1 ABCC2 LTBP4 ZNF639	5.22e-05	199	110	7	3684_DN
Drug	STOCK1N-28457; Up 200; 20uM; MCF7; HT_HG-U133A	A2M HIVEP2 RIPK4 ZKSCAN5 RYR2 VPS13D MUC5AC	5.22e-05	199	110	7	6869_UP
Drug	Imipramine hydrochloride [113-52-0]; Up 200; 12.6uM; MCF7; HT_HG-U133A	HLCS MAST2 RYR2 VPS13D C3 MUC5AC ZNF639	5.39e-05	200	110	7	1685_UP
Drug	Nizatidine [76963-41-2]; Down 200; 12uM; MCF7; HT_HG-U133A	HIVEP2 HLCS ZKSCAN5 VPS13D PDE8B LTBP4 ZNF639	5.39e-05	200	110	7	3385_DN
Drug	Amitrole	XDH APP TG MUC5AC	5.50e-05	43	110	4	ctd:D000640
Drug	thymidine glycol monophosphate	TPSAB1 TPSB2	6.92e-05	3	110	2	CID000165415
Drug	DMF 3	TG C3	6.92e-05	3	110	2	CID000007026
Drug	4,5-dihydroxyphthalate	APP PHKA2	6.92e-05	3	110	2	CID000045746
Drug	methylamine	A2M CTRC XDH RCAN3 TMTC1 C3 MVP	1.04e-04	222	110	7	CID000006329
Drug	NSC49103	TPSAB1 SPSB1 TPSB2	1.18e-04	20	110	3	CID000005251
Drug	S-Hydroxycysteine	ACAT2 C3	1.38e-04	4	110	2	DB01915
Drug	Brunfelsamidine	TPSAB1 TPSB2	1.38e-04	4	110	2	CID005281683
Drug	imidazole	GPD2 PDE4D CTRC HLCS PDE8B C3 ADAM17	1.77e-04	242	110	7	CID000000795
Drug	RO033-4649	APP VCAN PLEC	1.81e-04	23	110	3	CID000506900
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	ZSCAN31 SOCS6 APP RYR2 CIAPIN1 PAN2	2.03e-04	174	110	6	3993_DN
Drug	AC1LX9D5	DAG1 APP C3	2.06e-04	24	110	3	CID001747892
Drug	Piperonyl Butoxide	GLS2 MLEC XDH APP ZIC1 WDR90 PLEC ABCC2 LTBP4	2.15e-04	423	110	9	ctd:D010882
Drug	GLA-27	RELN C3	2.29e-04	5	110	2	CID000163574
Drug	AC1NRA7B	A2M ABCC2	2.29e-04	5	110	2	CID005287741
Drug	pyrimidin-4-one	XDH APP	2.29e-04	5	110	2	CID000020695
Drug	Benzethonium chloride [121-54-0]; Up 200; 9uM; MCF7; HT_HG-U133A	CA9 PAMR1 MUC5B VCAN LTBP4 AHNAK2	2.44e-04	180	110	6	6070_UP
Drug	Corticosterone [50-22-6]; Up 200; 11.6uM; MCF7; HT_HG-U133A	HIVEP2 SOCS6 RYR2 C3 LTBP4 AHNAK2	2.74e-04	184	110	6	3244_UP
Drug	Chloropyramine hydrochloride [6170-42-9]; Up 200; 12.2uM; PC3; HT_HG-U133A	A2M PDE4D GLS2 RYR2 ABCC2 LTBP4	2.99e-04	187	110	6	4589_UP
Drug	Salbutamol [18559-94-9]; Up 200; 16.8uM; PC3; HT_HG-U133A	PDE4D HLCS MUC5B ITGAL RYR2 C3	2.99e-04	187	110	6	3677_UP
Drug	olanzapine	A2M RELN APP PDE8B C3	3.06e-04	121	110	5	ctd:C076029
Drug	Beclomethasone dipropionate [5534-09-8]; Up 200; 7.6uM; PC3; HT_HG-U133A	HLCS DPYSL4 RYR2 TG VCAN ZNF639	3.35e-04	191	110	6	4580_UP
Drug	Ethisterone [434-03-7]; Down 200; 12.8uM; MCF7; HT_HG-U133A	A2M HLCS XDH MUC5B PLXNA2 ZNF639	3.35e-04	191	110	6	3975_DN
Drug	Sanguinarine [2447-54-3]; Down 200; 12uM; MCF7; HT_HG-U133A	FLNB HLCS SOCS6 DBT VPS13D AGL	3.35e-04	191	110	6	4168_DN
Drug	Attpsa	TPSAB1 TPSB2	3.43e-04	6	110	2	CID005487511
Drug	Ethaverine hydrochloride [985-13-7]; Down 200; 9.2uM; MCF7; HT_HG-U133A	HLCS DAG1 ZKSCAN5 RCAN3 C3 AHNAK2	3.44e-04	192	110	6	3375_DN
Drug	Norgestrel-(-)-D [797-63-7]; Up 200; 12.8uM; PC3; HT_HG-U133A	PDE4D XDH MUC5B APP MEGF8 MUC5AC	3.54e-04	193	110	6	3708_UP
Drug	Selegiline hydrochloride [14611-52-0]; Up 200; 17.8uM; MCF7; HT_HG-U133A	A2M RYR2 VPS13D C3 ABCC2 LTBP4	3.54e-04	193	110	6	4146_UP
Drug	AG-028671 [847803-03-6]; Up 200; 10uM; MCF7; HT_HG-U133A	GLS2 HLCS APP GLE1 ADAM17 PLEC	3.54e-04	193	110	6	6587_UP
Drug	ICI182,780; Up 200; 1uM; MCF7; HT_HG-U133A	ZSCAN31 APP RYR2 LTBP4 PLXNA2 ZNF639	3.54e-04	193	110	6	7490_UP
Drug	Cyclacillin [3485-14-1]; Up 200; 11.8uM; PC3; HT_HG-U133A	PDE4D HLCS XDH MAST2 PHKA2 VPS13D	3.54e-04	193	110	6	4536_UP
Drug	Iopanoic acid [96-83-3]; Down 200; 7uM; MCF7; HT_HG-U133A	A2M MAST2 ZKSCAN5 RYR2 PHKA2 LTBP4	3.64e-04	194	110	6	5448_DN
Drug	Carbetapentane citrate [23142-01-0]; Up 200; 7.6uM; MCF7; HT_HG-U133A	CA9 A2M RYR2 MEGF8 ABCC2 LTBP4	3.64e-04	194	110	6	5610_UP
Drug	PF-00875133-00 [351322-64-0]; Up 200; 10uM; MCF7; HT_HG-U133A	HLCS MAST2 PDE8B PLEC MUC5AC ZNF639	3.64e-04	194	110	6	5923_UP
Drug	Ampyrone [83-07-8]; Down 200; 19.6uM; PC3; HT_HG-U133A	ARFGEF2 DBT APP MAST2 GLE1 VCAN	3.64e-04	194	110	6	2086_DN
Drug	Resveratrol [501-36-0]; Up 200; 17.6uM; MCF7; HT_HG-U133A	CA9 ADAM18 ZKSCAN7 ITGAL ADAMTSL3 AHNAK2	3.74e-04	195	110	6	2865_UP
Drug	Dobutamine hydrochloride [49745-95-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A	CPLANE2 APP MAST2 MEGF8 C3 ABCC2	3.74e-04	195	110	6	5386_UP
Drug	Nitrofural [59-87-0]; Down 200; 20.2uM; MCF7; HT_HG-U133A	SPSB1 MAST2 ARHGAP44 C3 PLEC MVP	3.74e-04	195	110	6	3320_DN
Drug	ST021200; Down 200; 10uM; PC3; HT_HG-U133A	DAG1 DBT VPS13D VCAN ADAM17 PLEC	3.74e-04	195	110	6	7493_DN
Drug	AH23848 hemicalcium salt hydrate; Up 200; 1uM; MCF7; HT_HG-U133A	RIPK4 DBT APP RPGR MVP HDLBP	3.74e-04	195	110	6	6903_UP
Drug	Betahistine mesylate [54856-23-4]; Up 200; 17.2uM; MCF7; HT_HG-U133A	HLCS XDH RYR2 VPS13D LTBP4 MUC5AC	3.74e-04	195	110	6	2833_UP
Drug	PNU-0230031 [267429-39-0]; Down 200; 10uM; PC3; HT_HG-U133A	GLS2 HLCS APP VCAN PLXNA2 ZNF639	3.74e-04	195	110	6	3732_DN
Drug	Flunisolide [3385-03-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A	SOCS6 MAST2 ZKSCAN5 PHKA2 ADAM17 LTBP4	3.74e-04	195	110	6	3923_DN
Drug	Furazolidone [67-45-8]; Down 200; 17.8uM; MCF7; HT_HG-U133A	XDH WDR59 VPS13D C3 ADAM17 LTBP4	3.74e-04	195	110	6	3358_DN
Drug	Enoxacin [74011-58-8]; Down 200; 12.4uM; HL60; HG-U133A	XDH APP VPS13D GLE1 POP1 HDLBP	3.84e-04	196	110	6	1597_DN
Drug	chlorpromazine hydrochloride; Up 200; 1uM; MCF7; HT_HG-U133A	A2M RYR2 MEGF8 ABCC2 MUC5AC PLXNA2	3.84e-04	196	110	6	5577_UP
Drug	Debrisoquin sulfate [581-88-4]; Up 200; 9uM; MCF7; HT_HG-U133A	EPPK1 APP RYR2 ARHGAP44 RPGR HDLBP	3.84e-04	196	110	6	5288_UP
Drug	Quinethazone [73-49-4]; Up 200; 13.8uM; PC3; HT_HG-U133A	CA9 A2M DCHS2 PDE4D PDE8B LTBP4	3.84e-04	196	110	6	3793_UP
Drug	Tremorine dihydrochloride [300-68-5]; Up 200; 15uM; MCF7; HT_HG-U133A	XDH ZKSCAN5 VPS13D PLEC HSD17B11 ZNF639	3.84e-04	196	110	6	6273_UP
Drug	Ethotoin [86-35-1]; Down 200; 19.6uM; MCF7; HT_HG-U133A	SOCS6 MAST2 WDR59 VPS13D POP1 C3	3.84e-04	196	110	6	3892_DN
Drug	Terconazole [67915-31-5]; Down 200; 7.6uM; MCF7; HT_HG-U133A	GPD2 GLS2 HLCS RIPK4 ADAM17 RPGR	3.84e-04	196	110	6	2844_DN
Drug	Digoxigenin [1672-46-4]; Down 200; 10.2uM; MCF7; HT_HG-U133A	A2M HLCS C3 ABCC2 LTBP4 MVP	3.84e-04	196	110	6	3397_DN
Drug	Diphenhydramine hydrochloride [147-24-0]; Up 200; 13.8uM; MCF7; HT_HG-U133A	ZSCAN31 APP VPS13D PDE8B RPGR MUC5AC	3.84e-04	196	110	6	1708_UP
Drug	naphthol AS-D chloroacetate	A2M TPSAB1 ITGAL TPSB2	3.91e-04	71	110	4	CID000160247
Drug	Tubocurarine chloride pentahydrate (+) [6989-98-6]; Down 200; 5.2uM; MCF7; HT_HG-U133A	A2M HLCS VPS13D GLE1 RPGR LTBP4	3.95e-04	197	110	6	5449_DN
Drug	0179445-0000 [211246-22-9]; Up 200; 1uM; MCF7; HT_HG-U133A	HLCS DBT RYR2 LTBP4 UNC13A PLXNA2	3.95e-04	197	110	6	4758_UP
Drug	Quinic acid [86-68-0]; Up 200; 19.6uM; MCF7; HT_HG-U133A	A2M GPD2 ZSCAN31 DBT WDR59 MUC5AC	3.95e-04	197	110	6	3540_UP
Drug	rosiglitazone; Up 200; 10uM; MCF7; HT_HG-U133A_EA	SPSB1 HLCS MAST2 RYR2 PDE8B ZNF639	3.95e-04	197	110	6	1013_UP
Drug	PNU-0251126 [267429-19-6]; Down 200; 1uM; PC3; HT_HG-U133A	HIVEP2 GLS2 VPS13D MEGF8 ADAM17 ZNF639	3.95e-04	197	110	6	3692_DN
Drug	Triprolidine hydrochloride [550-70-9]; Down 200; 12.8uM; PC3; HT_HG-U133A	HIVEP2 DBT VPS13D GLE1 PAN2 PLXNA2	3.95e-04	197	110	6	7248_DN
Drug	rottlerin; Down 200; 10uM; MCF7; HT_HG-U133A_EA	FLNB ARFGEF2 DAG1 ZKSCAN5 VPS13D PLEC	3.95e-04	197	110	6	825_DN
Drug	Nitrocaramiphen hydrochloride; Up 200; 10.8uM; MCF7; HT_HG-U133A	XDH RYR2 VCAN ABCC2 MVP AHNAK2	3.95e-04	197	110	6	7464_UP
Drug	Metformin hydrochloride [1115-70-4]; Up 200; 24.2uM; HL60; HT_HG-U133A	ARFGEF2 SOCS6 APP VCAN ADAM17 HDLBP	3.95e-04	197	110	6	1858_UP
Disease	Periventricular Nodular Heterotopia	FLNA ARFGEF2 TMTC3	1.70e-06	7	109	3	C1868720
Disease	Periventricular nodular heterotopia	FLNA ARFGEF2	1.35e-05	2	109	2	cv:C1868720
Disease	myofibrillar myopathy 5 (implicated_via_orthology)	FLNA FLNB	4.05e-05	3	109	2	DOID:0080096 (implicated_via_orthology)
Disease	distal muscular dystrophy 4 (implicated_via_orthology)	FLNA FLNB	4.05e-05	3	109	2	DOID:0111190 (implicated_via_orthology)
Disease	Heterotopia, Periventricular, Autosomal Recessive	FAT4 ARFGEF2	4.05e-05	3	109	2	C1842563
Disease	cortical thickness	FNIP2 A2M FLNB RELN GLS2 ARFGEF2 DPYSL4 MAST2 ADAMTSL3 TG VPS13D VCAN PLEC PLXNA2	6.21e-05	1113	109	14	EFO_0004840
Disease	unipolar depression, depressive symptom measurement	FNIP2 ZSCAN31 ARFGEF2	1.20e-04	26	109	3	EFO_0003761, EFO_0007006
Disease	Liver Cirrhosis, Experimental	A2M FLNA GLS2 PAMR1 APP ITGAL FAT1 AGL ADAM17 ABCC2 MVP	1.40e-04	774	109	11	C0023893
Disease	Age related macular degeneration	HMCN1 C3 RPGR	1.85e-04	30	109	3	C0242383
Disease	periventricular nodular heterotopia (is_implicated_in)	FLNA ARFGEF2	2.01e-04	6	109	2	DOID:0050454 (is_implicated_in)
Disease	peritonitis (biomarker_via_orthology)	A2M XDH	2.81e-04	7	109	2	DOID:8283 (biomarker_via_orthology)
Disease	visceral heterotaxy (implicated_via_orthology)	CPLANE2 PHKA2 MEGF8	3.48e-04	37	109	3	DOID:0050545 (implicated_via_orthology)
Disease	tryptase beta-2 measurement	TPSAB1 TPSB2	4.79e-04	9	109	2	EFO_0008306
Disease	cerebrospinal fluid biomarker measurement, alpha synuclein measurement	APP GABPA	5.97e-04	10	109	2	EFO_0006794, EFO_0009323
Disease	Endogenous depression	RELN APP TG	6.63e-04	46	109	3	C0011573
Disease	pulmonary fibrosis	MUC5B MUC5AC	7.28e-04	11	109	2	EFO_0009448
Disease	Depressive disorder	A2M RELN PDE4D APP TG GABPA	7.30e-04	289	109	6	C0011581
Disease	craniosynostosis (is_implicated_in)	FLNA ZIC1	8.71e-04	12	109	2	DOID:2340 (is_implicated_in)
Disease	Fetal Alcohol Spectrum Disorders	CHL1 GABPA	1.03e-03	13	109	2	C2985290
Disease	rhinitis (biomarker_via_orthology)	C3 MUC5AC	1.03e-03	13	109	2	DOID:4483 (biomarker_via_orthology)
Disease	thalamus volume change measurement	SPSB1 FAT1	1.20e-03	14	109	2	EFO_0021496
Disease	Autosomal recessive limb-girdle muscular dystrophy	DAG1 PLEC	1.20e-03	14	109	2	cv:C2931907
Disease	lysophosphatidylethanolamine 18:0 measurement	MATN2 TMTC1	1.38e-03	15	109	2	EFO_0010367
Disease	Alzheimer's disease (is_implicated_in)	A2M APP C3 ADAM17	1.48e-03	132	109	4	DOID:10652 (is_implicated_in)
Disease	Glycogen storage disease	PHKA2 AGL	1.77e-03	17	109	2	cv:C0017919
Disease	Fetal Alcohol Syndrome	CHL1 GABPA	1.77e-03	17	109	2	C0015923
Disease	ascending aortic diameter	FLNB SPSB1 RYR2 HMCN1	1.84e-03	140	109	4	EFO_0021787
Disease	Age-related macular degeneration	HMCN1 C3	1.99e-03	18	109	2	cv:C0242383
Disease	osteochondrodysplasia (is_implicated_in)	FLNA FLNB	2.22e-03	19	109	2	DOID:2256 (is_implicated_in)
Disease	aortic measurement	FLNB SPSB1 RYR2 HMCN1 LTBP4	2.44e-03	251	109	5	EFO_0020865
Disease	urticaria	TPSAB1 TPSB2	2.46e-03	20	109	2	EFO_0005531
Disease	COVID-19 (is_implicated_in)	A2M C3	2.71e-03	21	109	2	DOID:0080600 (is_implicated_in)
Disease	HIV-1 infection, Susceptibility to viral and mycobacterial infections	ADAM18 ADAM17	2.71e-03	21	109	2	EFO_0000180, Orphanet_391311
Disease	muscular dystrophy (implicated_via_orthology)	DAG1 SGCZ	2.71e-03	21	109	2	DOID:9884 (implicated_via_orthology)
Disease	susceptibility to mumps measurement	PDE4D ADAM18 ADAM17	2.73e-03	75	109	3	EFO_0008404
Disease	interleukin 18 measurement	RELN XDH WDR59	2.83e-03	76	109	3	EFO_0004581
Disease	sphingomyelin 24:1 measurement	PDE4D SGCZ	3.25e-03	23	109	2	EFO_0010398
Disease	white matter microstructure measurement	EPPK1 DAG1 MAST2 VCAN CARD11 PLEC	3.32e-03	390	109	6	EFO_0005674

Protein segments in the cluster

Peptide	Gene	Start	Entry
PVGEVSVHVELFTHP	UNC13A	1526	Q9UPW8
TIVVKVPGQEDSHHE	BANP	161	Q8N9N5
VVESGHGVSHVVPIS	ACTL7B	196	Q9Y614
HGVSHVVPISEGDVL	ACTL7B	201	Q9Y614
DTEVGHQAHEHTEPV	VCAN	1526	P13611
SVPVADGQPHEVSVH	CSPG4	276	Q6UVK1
IHHGVVEVDAAVTPE	APP	731	P05067
AHEGSEGIFLHVTVP	ADAM18	16	Q9Y3Q7
HPSVVETDGHARVVV	ARHGEF5	736	Q12774
VKVESVDHDSCVHGP	FAT4	3796	Q6V0I7
AVTSPHIEIHEGTIL	ARFGEF2	146	Q9Y6D5
AHDAQGDVPVTVTVH	C3	46	P01024
TPEEVQSVREHLGHE	CIAPIN1	136	Q6FI81
EVASHHEAAFPIAVV	GLE1	491	Q53GS7
HIVTVASAAGHVSVP	HSD17B11	166	Q8NBQ5
GHARLVHVEEPHTET	A2M	716	P01023
GSEHTVEGHRFPAEI	CA9	236	Q16790
AHGTVLAPGEVVHDE	MUC5B	756	Q9HC84
HEVDSALVVESEHPH	NBPF4	236	Q96M43
LHAGTESTPSVVVHV	RCAN3	186	Q9UKA8
VETPAVSHDEHTHQE	DBT	151	P11182
VEVTEEHKPSAVAHV	FAT1	2051	Q14517
HSVVAEVGVPVSVSH	PAN2	66	Q504Q3
EVGVPVSVSHFDLHE	PAN2	71	Q504Q3
EVTQTFHITLHPVDD	FRAS1	2296	Q86XX4
VTHHPIPSEEDINFI	GPD2	361	P43304
SIGSEPHEDHVFLVA	MATN2	206	O00339
TLTVIAEEEHHGPPS	MAGI3	931	Q5TCQ9
VHAVGERVHSEAISP	KIAA1671	736	Q9BY89
LGTATHDFHVIVEEP	CHL1	316	O00533
THPIEVFEPGAEHIV	CHL1	1031	O00533
VTGVDTDPHFIIHVP	ITIH1	666	P19827
FDRVGHSTAHDEIIP	MLEC	156	Q14165
PADTVEVVIDPDAHH	GABPA	116	Q06546
EVVIDPDAHHAESEA	GABPA	121	Q06546
QVHQEGGEVVTVHPD	HLCS	696	P50747
HSVLSDLHEAVPTVV	DAG1	51	Q14118
TPEEIIHPDVDEHSV	FLNB	216	O75369
DFSEIAHHVQVAGVP	PLXNA2	886	O75051
IFASAIHDVDHPGVS	PDE4D	496	Q08499
VAALIAATVHDVDHP	PDE8B	646	O95263
FVVRVAPDTGVHTVH	MEGF8	2511	Q7Z7M0
SGEGAVVLPTIHDHI	LRRC4	591	Q9HBW1
TALHVAAAEGHIEVV	GLS2	521	Q9UI32
TFLRHTGPEEEATVH	ABCC2	861	Q92887
SHPEVSIEHLGQVVQ	MUC5AC	1796	P98088
SHPEVSIEHLGQVVQ	MUC5AC	4006	P98088
SHPIEVSVGHPSEVD	NPEPPSL1	416	A6NEC2
VTVQDTEAHVPDVHE	MVP	251	Q14764
TEAHVPDVHEEVLGV	MVP	256	Q14764
GAPTDVTVHPHLAEI	RELN	181	P78509
GEDTHTVSLTVHVLP	HMCN1	4246	Q96RW7
AESPTVHVEVHQRGS	TRIP13	16	Q15645
PGVIVTHVSVHDVDL	DCHS2	2361	Q6V1P9
SVHTVGEDTEETPHR	POP1	451	Q99575
HGNPEEVTVVFEALH	ITGA9	956	Q13797
AGLEVPVVHHETTGI	CPLANE2	76	Q9BU20
EGHVLSHPEEVEAEA	DPYSL4	221	O14531
EEGSLFVGVDTIHVH	CTRC	96	Q99895
EGVHTVHVTFAGVPI	FLNA	451	P21333
TVHHPVLDEPIAEAV	FNIP2	981	Q9P278
SELTVPCDIVIDHHV	CCDC73	696	Q6ZRK6
DITVHVPQGHVAVGE	MACC1	231	Q6ZN28
NGEPVHGLVHTEVVE	MAST2	1161	Q6P0Q8
SVHVEHPQEASVVVH	LTBP4	221	Q8N2S1
VPSNHEHIEVTRIDG	RYR2	1261	Q92736
SHPIEVSVGHPSEVD	NPEPPS	416	P55786
STIVVEEGHEGLTHF	CARD11	116	Q9BXL7
APHETSFGEEVEVHN	DDB1	776	Q16531
HGPGQTVSEEATEVH	FAM153B	196	P0C7A2
HVPGQTVSEEATGVH	FAM153B	296	P0C7A2
SVIHVLPDEVEHCQS	PHKA2	226	P46019
EEQHEDHGIPVSVTD	PAMR1	631	Q6UXH9
VPVHLSCGDEHSAVV	RPGR	36	Q92834
ELEEPVNVSSHVHTV	TPSAB1	126	Q15661
ELEEPVNVSSHVHTV	TPSB2	126	P20231
HEVDSALVVESEHPH	NBPF5P	236	Q86XG9
HEVDSALVVESEHPH	NBPF6	236	Q5VWK0
ALAIHTEVVEHPEVF	PRORSD1P	16	A6NEY8
IATGGVIDPVHSHRV	EPPK1	5011	P58107
HTVGIEVGAHFLEAV	NOM1	431	Q5C9Z4
VEDPVHGIHLETFTQ	PRRC1	351	Q96M27
TEGAVFGHSVETPHI	SGCZ	171	Q96LD1
IHDHNIPTLEAVVGV	ITGAL	961	P20701
STDLVHFDIPSIHIE	ARHGAP44	771	Q17R89
HGHSEVVEELVSADV	RIPK4	761	P57078
PIVESVVHEGDLHDP	AHNAK2	4666	Q8IVF2
TGHVVGEPDSRVLAH	ADAM17	116	P78536
VTHETSAHEGQTEAP	UCHL3	146	P15374
GVHIPFDVHHVESLA	ZNF653	241	Q96CK0
GTHVLTHESAEVPVA	WDR90	331	Q96KV7
EHHPESGEEAVAVVE	ZSCAN31	101	Q96LW9
EVHTAEDVPIAVEVH	ZNF639	131	Q9UID6
IPTEHSVLESHESEG	ZSCAN30	266	Q86W11
FAVHPIHTEAVAGIV	TMTC1	151	Q8IUR5
TVAPEDVSEVIFGHV	ACAT2	46	Q9BWD1
THAVVGVATADAPLH	SPSB1	111	Q96BD6
HIIGAVVADTPEHTQ	XDH	666	P47989
GVIDPVHSHRVPVDV	PLEC	2951	Q15149
IPEHHVIVSASSDGF	PAK1IP1	256	Q9NWT1
LNTPVHTFVGHDDVV	WDR59	271	Q6PJI9
ELVTHVTVEHVGGPE	ZIC1	251	Q15915
VRAHHPETGEEAVTV	ZSCAN16	101	Q9H4T2
EPHEATEGVVDFHIA	ZNF792	236	Q3KQV3
LHHPESGEEAVAVVE	ZKSCAN7	116	Q9P0L1
VHIHFPVEGSGSDTV	HDLBP	686	Q00341
LFAVHPIHTEAVTGV	TMTC3	126	Q6ZXV5
SVVHHVSDSGPAAEL	TREML1	211	Q86YW5
AGTAHIDGDHIVVSV	ZNF711	31	Q9Y462
FELPSVQEGHVEVEH	HIVEP2	596	P31629
VVVDPSIRHFDVAHV	TG	2101	P01266
IAFDHSVPHVIEEDE	WDR87	701	Q6ZQQ6
PDVEGHTSIVDLIEH	SOCS6	446	O14544
PAEHFHEGEAVSVVG	TYSND1	426	Q2T9J0
REHHPESGEEAVAVI	ZKSCAN5	111	Q9Y2L8
TVEHVGGPEQSSHVC	ZIC5	446	Q96T25
DKEISHTVPDISIHG	VPS13D	2216	Q5THJ4
PEHNHLSVVVGGIVE	ADAMTSL3	1296	P82987
DEDIVAVTRHSPSIH	AGL	726	P35573